Parsons Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.83M Buy
243,066
+106,825
+78% +$2.84M 0.31% 71
2025
Q4
$3.39M Sell
136,241
-17,090
-11% -$431K 0.19% 123
2025
Q3
$3.91M Buy
153,331
+476
+0.3% +$11.7K 0.22% 105
2025
Q2
$3.71M Sell
152,855
-105,096
-41% -$2.45M 0.23% 99
2025
Q1
$6.54M Sell
257,951
-36,813
-12% -$963K 0.36% 61
2024
Q4
$7.82M Buy
294,764
+159,984
+119% +$4.34M 0.42% 46
2024
Q3
$3.9M Sell
134,780
-8,233
-6% -$240K 0.25% 86
2024
Q2
$4M Sell
143,013
-14,164
-9% -$390K 0.27% 81
2024
Q1
$4.36M Buy
157,177
+15,239
+11% +$423K 0.3% 79
2023
Q4
$4.09M Sell
141,938
-65,028
-31% -$1.97M 0.29% 80
2023
Q3
$6.87M Buy
206,966
+2,926
+1% +$103K 0.54% 39
2023
Q2
$7.48M Buy
204,040
+32,230
+19% +$1.25M 0.57% 35
2023
Q1
$7.01M Buy
171,810
+10,139
+6% +$438K 0.56% 36
2022
Q4
$8.28M Buy
161,671
+2,113
+1% +$101K 0.69% 31
2022
Q3
$6.98M Buy
159,558
+27
+0% +$1.31K 0.63% 31
2022
Q2
$8.36M Sell
159,531
-468
-0.3% -$23.8K 0.75% 27
2022
Q1
$8.28M Sell
159,999
-5,422
-3% -$281K 0.63% 31
2021
Q4
$9.77M Buy
165,421
+2,710
+2% +$134K 0.7% 28
2021
Q3
$7M Buy
162,711
+7,330
+5% +$325K 0.55% 38
2021
Q2
$6.08M Sell
155,381
-5,151
-3% -$200K 0.47% 46
2021
Q1
$5.82M Sell
160,532
-713
-0.4% -$25.3K 0.48% 42
2020
Q4
$5.93M Sell
161,245
-9,062
-5% -$332K 0.51% 41
2020
Q3
$5.93M Buy
170,307
+4,346
+3% +$152K 0.58% 37
2020
Q2
$5.15M Sell
165,961
-228
-0.1% -$7.75K 0.55% 41
2020
Q1
$5.15M Sell
166,189
-3,509
-2% -$120K 0.66% 36
2019
Q4
$6.31M Sell
169,698
-4,802
-3% -$171K 0.63% 36
2019
Q3
$5.95M Sell
174,500
-59,758
-26% -$2.17M 0.64% 33
2019
Q2
$9.63M Sell
234,258
-3,422
-1% -$136K 1.05% 19
2019
Q1
$9.58M Sell
237,680
-3,797
-2% -$152K 1.05% 16
2018
Q4
$10M Buy
241,477
+120
+0% +$4.98K 1.23% 13
2018
Q3
$10.1M Sell
241,357
-1,325
-0.5% -$51K 1.06% 13
2018
Q2
$8.35M Buy
242,682
+306
+0.1% +$10.5K 0.95% 17
2018
Q1
$8.16M Sell
242,376
-4,262
-2% -$147K 0.95% 17
2017
Q4
$8.48M Buy
246,638
+232
+0.1% +$7.91K 0.94% 17
2017
Q3
$8.35M Sell
246,406
-274
-0.1% -$8.81K 0.98% 17
2017
Q2
$7.86M Sell
246,680
-1,834
-0.7% -$57.8K 0.96% 19
2017
Q1
$8.07M Sell
248,514
-2,467
-1% -$77.8K 1.02% 16
2016
Q4
$7.73M Sell
250,981
-5,393
-2% -$165K 1.03% 15
2016
Q3
$8.24M Sell
256,374
-1,107
-0.4% -$37K 1.11% 14
2016
Q2
$8.6M Buy
257,481
+17,930
+7% +$572K 1.17% 13
2016
Q1
$6.74M Buy
239,551
+49,159
+26% +$1.4M 0.92% 20
2015
Q4
$5.83M Buy
190,392
+42
+0% +$1.32K 0.82% 24
2015
Q3
$5.67M Buy
190,350
+2,503
+1% +$80.3K 0.83% 24
2015
Q2
$5.98M Buy
187,847
+7,259
+4% +$237K 0.79% 24
2015
Q1
$5.96M Buy
180,588
+17,523
+11% +$557K 0.84% 22
2014
Q4
$4.82M Buy
163,065
+3,265
+2% +$93.6K 0.64% 37
2014
Q3
$4.48M Sell
159,800
-6,357
-4% -$178K 0.62% 39
2014
Q2
$4.68M Sell
166,157
-3,798
-2% -$108K 0.64% 39
2014
Q1
$5.18M Sell
169,955
-7,398
-4% -$221K 0.74% 29
2013
Q4
$5.15M Buy
177,353
+1,455
+0.8% +$42.3K 0.77% 29
2013
Q3
$4.79M Buy
175,898
+1,674
+1% +$45.5K 0.79% 29
2013
Q2
$4.63M Buy
+174,224
New +$4.81M 0.79% 29

Other funds holding PFE

Parsons Capital Management's PFE Position: Q1 2026 in Review

Parsons Capital Management increased its Pfizer (PFE) stake by 78% in Q1 2026, buying an estimated $2.84M and bringing the position to 243,066 shares worth $6.83M. The position accounts for 0.31% of the portfolio, ranked #71.

Parsons Capital Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.1M in Q3 2018. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Parsons Capital Management held 243,066 shares of Pfizer worth $6.83M as of Q1 2026.
  • Parsons Capital Management bought 106,825 Pfizer shares in Q1 2026, an estimated $2.84M.
  • Pfizer made up 0.31% of Parsons Capital Management's portfolio in Q1 2026, its #71 holding.
  • Parsons Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Parsons Capital Management's Pfizer position peaked at $10.1M in Q3 2018.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Parsons Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.